Structural Genomics Consortium

What Structural Genomics Consortium does

The Structural Genomics Consortium (SGC) is a global public-private partnership founded in 2004 and registered as a charity in England and Wales (Charity No. 1097737). The consortium operates seven research sites across Canada, Germany, Sweden, the United Kingdom, the United States, and Brazil, with a network of more than 200 scientists spanning academia and pharmaceutical companies. SGC's mission is to determine the three-dimensional structures and functions of human proteins and to develop chemical probes for understudied targets, placing all research outputs in the public domain without patent restrictions under the Open Science Trust Agreement click-wrap framework.

SGC's technology platform integrates structural biology (X-ray crystallography and cryo-EM), high-throughput protein production, chemical biology (DNA-encoded library screening and affinity selection mass spectrometry), and AI-driven medicinal chemistry. Core outputs include more than 4,000 deposited protein structures and nearly 200 chemical probes, supported by open bioinformatics platforms (AIRCHECK, ChemBioPort, UbiHub, ChromoHub). The Target 2035 initiative coordinates a proteome-wide effort to develop a pharmacological tool for every human protein by 2035, while a formalized partnership with the University of Toronto's Acceleration Consortium integrates AI, robotics, and self-driving labs to automate Design-Make-Test-Analyze cycles for medicinal chemistry, embedded within the Collaborative Centre for Drug Discovery at UHN.

SGC operates a charitable public-private partnership model funded by pharmaceutical industry memberships, government grants, and philanthropic contributions. Industry partners — including Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Janssen, Merck KGaA, Pfizer, Takeda, and founding member GlaxoSmithKline — pay €5M over five years for Organizational Membership or €2M over five years for Technology Partnership. Public funders include the Canadian Institutes of Health Research, Genome Canada, the Wellcome Trust, the Ontario Ministry of Economic Development and Innovation, and the EU Innovative Medicines Initiative 2. The AC-SGC collaboration is supported by approximately $50M in industry funding, and the broader Acceleration Consortium has received a $200M Canada First Research Excellence Fund grant. SGC distributes all outputs — chemical probes, protein structures, data, and AI models — openly under the Open Science Trust Agreement.

Name

Structural Genomics Consortium

Legal name

Structural Genomics Consortium

Website

https://thesgc.org

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Drug Discovery Research

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAIALAD

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

SECONDARYFSANAHAE

Joint Venture CVC / Consortium Funds (Multi-corporate)

Financial & Insurance/Private Equity & Venture Capital/Corporate Venture Capital (CVC)

SECONDARYHLAGAHAM

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

• Open science drug discovery
• Structural genomics research
• Chemical probe development
• Protein structure determination
• Public-private partnership

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Public-Private Partnership Funding: SGC is a charitable organization (UK registered charity 1097737) funded by pharmaceutical industry partners, governments, and foundations. Current industry funding supports the AC-SGC collaboration at approximately $50M. Organizational Membership costs €5M over five years; Technology Partnership costs €2M over five years.
2. Donations: SGC accepts donations from philanthropies, disease foundations, and individuals to sustain and expand open science research. Donations help sustain critical work ensuring research remains freely available without patent restrictions.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

SGC is a global public-private partnership that produces and disseminates open-access research tools for early drug discovery, including 4,000+ protein structures, ~200 chemical probes for understudied human proteins, Target Enabling Packages (TEPs), AI-ready datasets (AIRCHECK), and self-driving medicinal chemistry lab capabilities. All outputs are made freely available to the scientific community under an Open Science Trust Agreement with no patent restrictions. The consortium operates across 7 countries with research sites focused on structural genomics, chemical biology, epigenetics, and AI-driven drug discovery.

Product overview

The Structural Genomics Consortium (SGC) operates as a global public-private partnership offering an integrated platform of open science products and services focused on understanding human protein functions and accelerating drug discovery. The core offering centers on Target 2035, a global initiative to develop pharmacological tools for every human protein, supported by complementary products: AIRCHECK (AI-ready chemical knowledge base), MAINFRAME (ML research network), Chemical Probes (selective small molecules), Protein Structures (4,000+ deposited structures), Target Enabling Packages, Protein Contribution Network, bioinformatics resources (ChemBioPort, UbiHub, ChromoHub), BEACON benchmarking platform, SGC Open Chemistry Networks, Patient Tissue Platform, and Open Lab Notebooks. All research outputs are made freely available without patent restrictions.

Differentiator

Problem solved

Functional benefit

Brands

• Target 2035: A global open science initiative that aims to develop a pharmacological tool (chemical probe) for every human protein by 2035
• AIRCHECK
• MAINFRAME
• BEACON
• Protein Contribution Network
• Women's and Children's Health Initiative
• Open Chemistry Networks

Products and services

• Target 2035

Quantifiable outcome

• 4,000+ protein structures deposited into public datasets
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Partnerships

Six partnerships are on record, tiered core, key and supporting.

• Acceleration Consortium (AC), University of TorontocoreStrategic or Co-development Partner · 4 June 2026Formalized partnership between SGC and the Acceleration Consortium to tackle bioactive molecule development for early drug discovery. The AC-SGC Medicinal Chemistry Self-Driving Lab (SDL) integrates AI, robotics, and advanced computing to automate iterative Design-Make-Test-Analyze cycles. The SDL operates under SGC's open science model and is embedded within the Collaborative Centre for Drug Discovery at UHN, supported by ~$50M in industry funding. The collaboration advances Target 2035 by enabling scalable AI-driven medicinal chemistry.
• End AxDkeyStrategic or Co-development Partner · 1 January 2025End AxD Grant Program selected SGC researchers (Alison Axtman at SGC-UNC and Levon Halabelian at SGC-Toronto) to develop first small-molecule GFAP ligands for Alexander disease. Five projects selected from 24 international applications.
• Life TechnologiessupportingStrategic or Co-development Partner · 19 July 2012Life Technologies signed collaborative agreement with SGC to develop the first antibody master set for epigenetic studies — 200 highly-specific renewable recombinant antibodies for high-impact epigenetics targets.
• BEACON (CACHE, DREAM, CASP, OpenADMET)keyStrategic or Co-development PartnerBEACON is a benchmarking super-consortium partnering with Target 2035 to provide a platform for computational scientists to benchmark hit-finding algorithms in real-world settings with experimental testing of model predictions. Includes CACHE, DREAM, CASP, and OpenADMET.
• Diamond Light Source LimitedsupportingTechnology or IntegrationDiamond Light Source provides synchrotron radiation facilities used by SGC for X-ray crystallography of protein structures.
• Tanenbaum Open Science InstitutesupportingStrategic or Co-development PartnerCo-founded by Dr. Guy Rouleau, The Tanenbaum Open Science Institute at McGill established one of the world's first institutional models fully committed to open science, aligning with SGC's mission.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Isomorphic Labs: Alphabet-owned AI drug discovery company leveraging DeepMind's protein-structure and chemistry AI. A broad industry incumbent pursuing similar AI-driven drug discovery outcomes as SGC's Target 2035 with significantly larger parent-company resources.
• Schrödinger, Inc. Established commercial platform provider for physics-based computational chemistry and AI-driven molecular design. Comparable to SGC's AIRCHECK and BEACON activities at a commercial, for-profit scale, addressing overlapping customers in AI drug discovery.

Direct peers

• Critical Path Institute (C-Path): US non-profit public-private partnership generating pre-competitive data, methods, and regulatory tools across multiple disease areas. Closely comparable operating model to SGC's PPP structure and consortium-driven drug development approach.
• Medicines for Malaria Venture (MMV): Product Development Partnership (PDP) coordinating public, private, and philanthropic funding for malaria drug R&D with outputs made openly available. Directly comparable mission-aligned non-profit drug discovery partnership model.
• EUbOPEN (Enabling and Unlocking Biology in the OPEN): EU-funded IMI public-private partnership for open chemical biology and target enabling across the druggable proteome. Directly comparable as a peer consortium model in the same open-science ecosystem as SGC and listed as one of SGC's initiatives.
• Medicines Discovery Catapult: UK-based non-profit, government-funded preclinical drug discovery catalyst operating national infrastructure for medicinal chemistry and target validation. Comparable to SGC as a publicly-funded drug-discovery support organization serving UK and global pharma partners.
• Drugs for Neglected Diseases initiative (DNDi): International non-profit drug discovery organization that develops treatments for neglected diseases using a virtual, partnership-based R&D model with open knowledge sharing. Comparable to SGC's non-commercial, multi-stakeholder, open-output approach to drug R&D.

Emerging players

• Insitro: AI-native biotech combining machine learning with high-throughput biology for target identification and drug discovery. Comparable as an emerging player in the same ML-driven, large-data drug discovery space that SGC's AIRCHECK/MAINFRAME ecosystem serves.
• Broad Institute: Major academic biomedical research organization with significant open-science structural biology, chemical biology, and therapeutic discovery programs. Comparable in operating model (academic, open outputs, multi-stakeholder funding) and in overlapping research areas with SGC's Target 2035 mission.
• Recursion Pharmaceuticals: AI-driven drug discovery company generating proprietary biological datasets and using machine learning to identify novel therapeutics. Overlaps with SGC's AI/ML drug discovery and large-scale protein-ligand screening remit, but operates in a for-profit, proprietary-data model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/pkisandtell
• Facebookfacebook.com/structuralgenomicsconsortium
• LinkedInlinkedin.com/company/structural-genomics-consortium-sgc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Structural Genomics Consortium